• Altschuler EL, Kast RE 2004 Bupropion for Blau syndrome. Med. Hypotheses 62: 297-298.

• Altschuler EL, Kast RE 2005 Bupropion for fatigue and as a tumor necrosis factor-alpha lowering agent in primary biliary cirrhosis. Med. Hypotheses 64: 118-119.

• Berrettini WH, Lerman CE 2005 Pharmacotherapy and pharmacogenetics of nicotine dependence. Am. J. Psychiatry 162: 1441-1451. *

• Bragin V, Chemodanova M, Dzhafarova N, Bragin I, Czerniawski JL, Aliev G 2005 Integrated treatment approach improves cognitive function in demented and clinically depressed patients. Am. J. Alzheimers Dis. Other Demen. 20: 21-26.

• Brustolim D, Ribeiro-Dos-Santos R, Kast RE, Altschuler EL, Soares MB 2006 A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int. Immunopharmacol. 6: 903-907.

• Carleton BC, Smith MA, Gelin MN, Heathcote SC 2007 Paediatric adverse drug reaction reporting: understanding and future directions. Can. J. Clin. Pharmacol. 14: e45-e57.

• Cassano P, Fava M 2004 Tolerability issues during long-term treatment with antidepressants. Ann. Clin. Psychiatry 16: 15-25.

• Cassis TB, Callen JP 2005 Bupropion-induced subacute cutaneous lupus erythematosus. Australas. J. Dermatol. 46: 266-269.

• Crone CC, Gabriel GM 2004 Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin. Pharmacokinet. 43: 361-394.

• Cullum JL, Wojciechowski AE, Pelletier G, Simpson JS 2004 Bupropion sustained release treatment reduces fatigue in cancer patients. Can. J. Psychiatry 49: 139-144. *

• Demyttenaere K, De Fruyt J, Stahl SM 2005 The many faces of fatigue in major depressive disorder. Int. J. Neuropsychopharmacol. 8: 93-105.

• Goodnick PJ, Sandoval R 1993 Psychotropic treatment of chronic fatigue syndrome and related disorders. J. Clin. Psychiatry 54: 13-20.

• Goodnick PJ, Sandoval R, Brickman A, Klimas NG 1992 Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. Biol. Psychiatry 32: 834-838.

• Hilsden RJ, Hodgins DC, Timmer A, Sutherland LR 2000 Helping patients with Crohn's disease quit smoking. Am. J. Gastroenterol. 95: 352-358. *

• Hofmann MH, Blievernicht JK, Klein K, Saussele T, Schaeffeler E, Schwab M, Zanger UM 2008 Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J. Pharmacol. Exp. Ther. 325: 284-292. *

• Humayun F, Shehab TM, Tworek JA, Fontana RJ 2007 A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: a case report. J. Med. Case Reports 1: 88. *

• Jamerson BD, Krishnan KR, Roberts J, Krishen A, Modell JG 2003 Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression. Psychopharmacol. Bull. 37: 67-78.

• Johnson GJ, Cosnes J, Mansfield JC 2005 Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment. Pharmacol. Ther. 21: 921-931. *

• Kane S, Altschuler EL, Kast RE 2003 Crohn's disease remission on bupropion. Gastroenterology 125: 1290. *

• Kanebratt KP, Andersson TB 2008 HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab. Dispos. 36: 137-145. *

• Kast RE 2005 Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities - the role of bupropion. Leuk. Res. 29: 1459-1463.

• Kast RE, Altschuler EL 2001 Remission of Crohn's disease on bupropion. Gastroenterology 121: 1260-1261. *

• Kast RE, Altschuler EL 2004 Bone density loss in Crohn's disease: role of TNF and potential for prevention by bupropion. Gut 53: 1056. *

• Khoo AL, Tham LS, Lee KH, Lim GK 2003 Acute liver failure with concurrent bupropion and carbimazole therapy. Ann. Pharmacother. 37: 220-223.

• Kirksey DF, Harto-Truax N 1983 Private practice evaluation of the safety and efficacy of bupropion in depressed outpatients. J. Clin. Psychiatry 44: 143-147.

• Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ 2006 Antidepressants and inflammatory bowel disease: a systematic review. Clin. Pract. Epidemol. Ment. Health 2: 24. *

• Oxenkrug GF 2007 Genetic and hormonal regulation of tryptophan kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging. Ann. N. Y. Acad. Sci. 1122: 35-49.

• Saussele T, Burk O, Blievernicht JK, Klein K, Nussler A, Nussler N, Hengstler JG, Eichelbaum M, Schwab M, Zanger UM 2007 Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. Clin. Pharmacol. Ther. 82: 265-274.

• Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S 2004 A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim. Care Companion J. Clin. Psychiatry 6: 159-166. *

• Tucker WE Jr 1983 Preclinical toxicology of bupropion: an overview. J. Clin. Psychiatry 44: 60-62.

• Wang JS, Zhu HJ, Gibson BB, Markowitz JS, Donovan JL, DeVane CL 2008 Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol. Pharm. Bull. 31: 231-234. *

• Wilkes S 2006 Bupropion. Drugs Today (Barc.) 42: 671-681.

Number of references = 32

www psc-literature.org